Thermo Fisher Scientific Durvalumab Polyclonal Antibody

Applications

Tested Dilution

Publications

ELISA (ELISA)

0.01-0.1 µg/mL

-

Product Specifications

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Durvalumab

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Storage conditions

-20°C or -80°C if preferred

Shipping conditions

Wet ice

Product Specific Information

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.

Durvalumab (Imfinzi) is a human IgG1kappa monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of cancer. It was developed by Medimmune/AstraZeneca. Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody which blocks the interaction of PD-L1 with the PD-1 and CD80 molecules.GenScript Anti-Durvalumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Durvalumab.

Target Information

Durvalumab with trade name Imfinzi, is an FDA-approved anti-cancer drug. It is known as a checkpoint inhibitor drug, developed by Medimmune/AstraZeneca. Durvalumab is a human IgG1 kappa monoclonal antibody. It blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.